{
    "NOTA.F": {
        "short_name": "NOVARTIS NAM. ADR 1",
        "long_name": "Novartis AG",
        "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "NOVN.SW": {
        "short_name": "NOVARTIS N",
        "long_name": "Novartis AG",
        "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "NOVNEE.SW": {
        "short_name": "NOVARTIS  N 2. LINIE",
        "long_name": "Novartis AG",
        "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "NVS": {
        "short_name": "Novartis AG",
        "long_name": "Novartis AG",
        "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "NVSEF": {
        "short_name": "NOVARTIS AG",
        "long_name": "Novartis AG",
        "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "NVSN.MX": {
        "short_name": "NOVARTIS AG",
        "long_name": "Novartis AG",
        "summary": "Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "RHHBF": {
        "short_name": "ROCHE HOLDINGS AG",
        "long_name": "Roche Holding AG",
        "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; collaboration and license agreement with Lead Pharma Holding B.V. to develop oral small molecules to treat a range of immune mediated diseases; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "RHHBY": {
        "short_name": "ROCHE HOLDINGS AG",
        "long_name": "Roche Holding AG",
        "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; collaboration and license agreement with Lead Pharma Holding B.V. to develop oral small molecules to treat a range of immune mediated diseases; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "RHHVF": {
        "short_name": "ROCHE HOLDINGS AG",
        "long_name": "Roche Holding AG",
        "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; collaboration and license agreement with Lead Pharma Holding B.V. to develop oral small molecules to treat a range of immune mediated diseases; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "RHO6.F": {
        "short_name": "ROCHE HLDG SP.ADR 1/8",
        "long_name": "Roche Holding AG",
        "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; collaboration and license agreement with Lead Pharma Holding B.V. to develop oral small molecules to treat a range of immune mediated diseases; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "ROGN.MX": {
        "short_name": "ROCHE HOLDINGS AG",
        "long_name": "Roche Holding AG",
        "summary": "Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; collaboration and license agreement with Lead Pharma Holding B.V. to develop oral small molecules to treat a range of immune mediated diseases; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company was founded in 1896 and is headquartered in Basel, Switzerland.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Switzerland",
        "city": "Basel"
    }
}